Issue Date: November 24, 2008
AstraZeneca Sells Off Biomanufacturing Plant
AstraZeneca has agreed to divest AstraZeneca Biotech Laboratory, a pilot plant in Södertälje, Sweden, for recombinant proteins and monoclonal antibodies, to Recipharm, a contract development and manufacturing organization. AstraZeneca will hold "a significant minority stake" in the new Recipharm subsidiary, which will supply material for Phase I and II tests of an AstraZeneca drug. AstraZeneca is consolidating all its biotech activities within MedImmune, which it acquired last year.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society